Q-omics provides the consensus-scored SH3BP5L profile across patient tissues and cancer cell-line models. SH3BP5L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SH3BP5L is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SH3BP5L RNA expression shows 19,969 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KIRC, and ACC as cancer lineages where SH3BP5L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SH3BP5L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SH3BP5L survival associations across molecular data types. SH3BP5L RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SH3BP5L RNA expression–survival associations across cancer types. High SH3BP5L expression shows unfavorable associations in ACC, LIHC and READ, but favorable associations in HNSC, KIRP and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SH3BP5L RNA expression.
This table summarizes SH3BP5L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SH3BP5L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SH3BP5L shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, LIHC, BLCA and KIRP. The KIRC box plot shows higher SH3BP5L RNA expression in tumor versus normal tissue (log2 FC = +0.757, t-test p < 0.001).
This table shows molecular features associated with SH3BP5L in patient tissues and cancer cell lines. In patient samples, SH3BP5L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SH3BP5L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
